Movement Alert｜Twist Bioscience Corp Intraday Decline 9.74% in Regular Trading, valuation debate persists after neutral initiation

Market Focus10-15 21:43

On October 15, Twist Bioscience Corp fell 9.74% in Regular Trading, trading at $131.78 per share, with turnover of $65.4247 million.

The move coincided with continued market digestion of recent analyst initiations that assigned neutral or hold-equivalent ratings and price targets close to prevailing trading levels, reinforcing near-term valuation disagreement around the synthetic DNA and AIDD validation services theme.

Recent coverage included Jefferies initiating with a Hold rating and a $150 price target, while UBS initiated with a Neutral rating and a $144 price target. Earlier supportive business developments, including collaboration with Eli Lilly's TuneLab and selection by Anthropic for an AI protein-design evaluation project, had helped drive enthusiasm, but the latest trading suggests investors remain focused on whether current valuations already reflect much of that growth potential.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment